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December 20101734 AbstractsMethods: One hundred fifty-three mesenteric ischemia patients had
both DUS and arteriography. ROC curves were used to analyze PSV, EDV,
and SMA or CA/aortic PSV ratio in detecting significant st.
Results: For SMA (151 arteries; 67 with 50%, 30 50%, 54 70% st.
based on angiography): Themost accurate PSVs for detecting50% and70%
st. were295 cm/s and400 cm/s with a sensitivity (sens.) of 87% and 72%,
specificity (spec.) 89% and 93%, PPV91% and 84%, andNPV84% and 85%, and
overall accuracy (OA) 88% and 85%, respectively. If Moneta’s criteria were
applied (PSV 275 cm/s for 70% st.) in our series, the sens., spec., PPV, NPV
andOAwere 92%, 59%, 56%, 93%, and 71%, respectively.When a PSVof300
cm/s (Bowersox for 50% st.) was applied, the sens., spec., PPV, NPV, and OA
were 86%, 89%, 91%, 83%, and 87%, respectively. Meanwhile, an EDV of45
cm/s (Zwolak) and70 cm/s (Perko) had a sens. of 79% and 47%, spec. 79%
and 98%, PPV 84% and 97%, NPV 72% and 57%, and OA 79% and 68% for
50% st., respectively. ROCanalysis showed that PSVwas better thanEDVand
SMA/aortic PSV ratio for50% st. of SMA and CA (P .003 and P .0005,
and P  .00001 and P  .04, respectively, Figs 1 and 2). For celiac arteries
(150 arteries; 45 with 50%, 43 50%, and 62 70% st.): The most
accurate PSVs for 50% and 70% st. were 240 cm/s and 320 cm/s
with sens. of 88% and 80%, spec. 83% and 89%, PPV 93% and 84%, NPV 74%
and 86%, and OA 87% and 85%, respectively. If Moneta’s criteria were
applied (PSV  200 cm/s for 70% st.), sens., spec., PPV, NPV, and OA
were 98%, 35%, 52%, 97%, and 61%, respectively.When a PSV of300 cm/s
(Bowersox) was applied, the sens., spec., PPV, NPV, and OA were 72%,
95%, 97%, 59%, and 79% for 50% stenosis. Meanwhile, an EDV of 45
cm/s (Zwolak) and 70 cm/s (Perko) had a sens. of 80% and 62%, spec.
58% and 88%, PPV 82% and 92%, NPV 53% and 49%, and OA 73% and 70%
for 50% st., respectively.
Conclusions: PSV values can be used in detecting significant SMA/CA
stenosis and were better than EDVs and ratios in detecting 50% st. of SMA
and CA. Previously published data must be validated in individual vascular labs.Impact of Metabolic Syndrome on SFA Interventions
Christopher J. Smolock, Javier Anaya Ayala, Jean Bismuth, Joseph J.
Naoum, Hosam F. El-Sayed, Heitham Hassoun, Eric K. Peden, Alan B.
Lumsden, Mark G. Davies, The Methodist Hospital, DeBakey Heart and
Vascular Center, Houston, Tex
Background: Metabolic syndrome (Met Syn) is an epidemic in the
United States and is associated with early onset of atherosclerosis, increased
thrombotic events and increased complications after cardiovascular inter-
vention. Met Syn is found in 50% of patients with peripheral vascular
disease however its impact on peripheral interventions is unknown. The aim
of this study is to determine the outcomes of superficial femoral artery (SFA)
interventions in patients with and without metabolic syndrome.
Methods: A database of patients undergoing endovascular treatment
of the SFA arteries between 1999 and 2009 was retrospectively queried.Met
Syn was defined as the presence of 3 of the following criteria: Blood
pressure 130 mmHg/ 85 mmHg; Triglycerides 150 mg/dL; HDL
 50 mg/dL for women and  40 mg/dL for men; Fasting blood glucose
 110 mg/dL; or body mass index (BMI)  30 kg/m2. Kaplan-Meier
survival analyses were performed to assess time-dependent outcomes. Factor
analyses were performed using a Cox proportional hazard model for time
dependent variables.
Results: One thousand fourteen limbs in 870 patients (64% male)
(average age 67 years) underwent endovascular treatment for symptomatic
SFA disease. Forty six percent met the criteria for Met Syn. Met Syn patients
were more likely to be female and to present with critical ischemia (rest
pain/tissue loss) and have more advanced TASC II SFA lesions (Table).
Mortality was equivalent but morbidity was higher in the Met Syn group.
The presence of Met Syn was associated with a decrease in clinical efficacy as
determined by freedom from recurrent symptoms, decreased primary pa-
tency, and an increase in major amputations (Table).
No Met Syn Met Syn P value
Number limbs at risk (n) 542 464 -
Male gender (%) 69 56 .001
Claudication (%) 62 46 .001
Rest pain/tissue loss (%) 38 54
TASC-II C and D lesions (%) 31 51 .001
30-day mortality (%) 1.3 0.2 .08
Morbidity (%) 9 14 .03
5-y freedom from recurrent symptoms (%) 73 67 .03
5-y primary patency (%) 66 56 .008
5-y assisted primary patency (%) 78 71 .06
5-y secondary patency (%) 78 71 .12
5-y limb salvage rate 87 78 .02
Conclusions: Met Syn is present in nearly half of patients presenting
with SFA disease. These patients present with more advanced disease and
have poorer symptomatic and functional outcomes compared to those
patients without Met Syn. Met Syn should be considered a risk factor for
poor outcomes during SFA interventions.
Surgical Site Infection after Arterial Intervention with a Groin Incision
Alexander J. Boyle, Justin M. Rizer, Kelley D. Hodgkiss-Harlow, Paul A.
Armstrong, Dennis F. Bandyk, University of South Florida, Tampa, Fla
Background: To investigate surgical site infection (SSI) statistics after
arterial interventions requiring a groin incision (a known risk factor for SSI);
including the influence of therapeutic vs prophylactic antibiotics, medical
comorbidities associated with SSI, causative microbiology, and treatment
outcomes.
Methods:A 1-year (2009) retrospective, consecutive-case audit of 372
lower limb arterial interventions (bypass grafting, n 236; AAA, stent graft,
n  86; endarterectomy/repair, n  50) requiring a groin incision. Occur-
rence of SSI within 30 days was correlated with age, gender, body mass
index, procedural therapeutic (active infection at time of procedure) vs
prophylactic (24 hours) antibiotic administration, medical comorbidities
(diabetes, renal insufficiency, coronary artery disease), and the presence of
methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization. In
the prophylactic patient group (n  311), the effect of adding an MRSA
antibiotic (vancomycin, 15-20 mg/kg - 2 doses; daptomycin, 6 mg/kg -
1-dose) to cephalosporin prophylaxis on SSI rate was analyzed.
Results: The overall SSI rate was 15%; higher (P  .001) in patients
receiving therapeutic (29%; 18 of 61) vs prophylactic (12%; 38 of 311)
antibiotics. Nasal MRSA colonization was associated with2 increase in SSI
(37% vs 16%; P  .01). SSI was lowest after open/EVAR AAA repair (5%)
compared to arterial bypass (21%) or endarterectomy/repair (20%) proce-
dures. The majority (64%) of SSIs were caused by gram  bacteria with
MRSA isolated from 37% of all positive cultures. The SSI rate in patients
receiving prophylactic antibiotics was 19% in the cephalosporin (cefazolin or
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the daptomycin  cefepime group (P  .01). The frequency of MRSA SSI
was similar (P .1) in patients receiving daptomycin (1.3%) compared to the
other prophylactic antibiotic regimens (4.8%). Overall, 41 (73%) of 56
patients with SSI required surgical therapy to achieve wound healing with
mean LOS increase of 12 days in SSI group. Outcomes at 30 days included
1.3% (4 patients) mortality and one prosthetic graft excised for infection.
Diabetes was associated with increased SSI (P  .04) while age, gender,
CAD, BMI, or renal insufficiency were not predictive of SSI.
Conclusions. This audit demonstrated one in seven patients devel-
ops SSI after arterial intervention involving the femoral artery. SSI risk
was higher in diabetics, after arterial bypass, with required therapeutic
antibiotics, and when nasal MRSA colonization was present. The most
common bacterial isolate was MRSA. The addition of a single-dose of
daptomycin (bactericidal to gram  organism including MRSA) to a
cephalosporin prophylaxis regimen significantly reduced SSI. Given the
trend to mandated hospital reporting of wound infection rates to con-
sumers, these SSI statistics are relevant and indicate an urgent need to
develop wound care strategies to augment primary healing and the
prevention of biofilm-mediated infection.
The Role of Statin Therapy and Angiotensin Blockade on Asymptom-
atic Moderate Carotid Artery Stenosis: A Clinical and Pharacoeco-
nomic Analysis
Christopher A. Durham, Bryan A. Ehlert, Steven C. Agle, Ashley C. Mays,
Frank M. Parker, William M. Bogey, Charles S. Powell, Michael C. Stoner,
East Carolina University, Greenville, NC
Introduction: Although the algorithm for symptomatic and severe
carotid disease is less controversial, questions remain as to the optimal
approach toward asymptomatic moderate carotid artery stenosis. The aim
of this study is to evaluate the 10-year outcome of patients presenting
with asymptomatic moderate carotid artery stenosis and to determine
which factors correlate with progression of disease to stroke or revascu-
larization.
Methods: A retrospective review of all new patients presenting with
asymptomatic moderate carotid artery stenosis from July 1998 to December
2001 was undertaken. Variables were recorded for all patient encounters
occurring through June 2010. A novel endpoint for a stroke or revascular-
ization event was defined:
● SORE - occurrence of ipsilateral cerebrovascular event or carotid revascu-
larization
Statin therapy and angiotensin blockade (STAB) were categorized as fol-
lows:
● STAB0 - Medical treatment with neither statin therapy nor angiotensin
blockade
● STAB1 - Medical treatment with only one of these therapies
● STAB2 - Medical treatment employing both therapies
To evaluate relative cost effectiveness of STAB therapy, an amortized model
based on our previously described cost efficacy model was used to analyze
the cost of each year without SORE.
Results: Over a 42-month period, 468 carotids in 366 patients were
evaluated for asymptomatic moderate carotid artery stenosis. The average
age of the entire cohort was 68.7 years, with a predominance of hyperten-
sion, coronary artery disease, hyperlipidemia, and smoking history. The
contralateral carotid was noted to have a greater than 50% stenosis in 68.0%
of patients. Antiplatelet therapy was employed in the treatment of 84.5% of
patients, compared to statin therapy in 63.5% and angiotensin blockade in
48.3% of patients. Over a mean follow-up of 6.6 years, SORE occurred in
150 (32.1%) carotid arteries. Cases were then stratified by occurrence of
SORE. Cases without SORE were noted to have a higher rate of bilateral
stenosis greater than 50%. Antiplatelet, statin, and angiotensin blockade
were found in significantly lower rates in cases progressing to SORE.
Multivariate analysis revealed only hyperlipidemia was predictive of SORE
(HR 1.524, CI 1.039-2.236, P  .03). Medical therapy with either a statin
or angiotensin blockade (STAB1) was protective against SORE (HR 0.505,
CI 0.350-0.730, P .01), and the additive effects of both statin therapy and
angiotensin pathway blockage (STAB2) were even more pronounced (HR
0.147, CI 0.089-0.244, P  .01). Bilateral stenosis greater than 50%
continued to be protective (HR 0.420, CI 0.302-0.584, P  .01) against
SORE. At 10 years, SORE-free survival was achieved in STAB2 in
82.7  4.6%. In STAB1, 56.3  5.0% had no SORE. The STAB0 cohort
had 29.3  5.4%without SORE (P .01). The cost model revealed the cost
per SORE-free year in the STAB2 cohort to be $1695.40  $275.60, less
than 50% that of either STAB1 ($3916.80  605.44) or STAB0
($4126.40  427.23) therapy (P  .01).Conclusion: These data are the first to demonstrate the clinical and
financial advantage of using both statin therapy and angiotensin pathway
blockage in patients with asymptomatic moderate carotid artery stenosis.
Avoidance of stroke and progression to surgery in these patients, with
concurrent cost savings, implies that this strategy should be standard of care
in this at-risk population.
Trends, Charges, and Outcomes in Endovascular Therapy for Periph-
eral Arterial Disease in Florida
Michael S. Hong, Khayree Butler, Trevan D. Fischer, Peter R. Nelson,
University of Florida, Gainesville, Fla
Background: We sought to define the current trends in the use of
endovascular procedures and the impact on the associated costs and
outcomes in Florida. These data can then be used as a baseline assessment
for the development of a statewide cooperative quality improvement
program.
Methods: The Agency for Healthcare Administration (AHCA) data-
base, which contains 100% of discharges from Florida hospitals, was queried
for peripheral arterial disease (PAD) from 2000 to 2008. Discharges from
ambulatory centers were also available from 2004 to 2008 allowing more
comprehensive analysis of endovascular procedures. Angioplasty, atherec-
tomy, and peripheral stents were identified either by respective CPT codes
for ambulatory procedures, or ICD-9 procedure codes for hospital-based
procedures, comprising the endovascular group. The open bypass group was
identified using ICD-9 codes for hospital data. Major amputations (above
knee to ankle), and minor amputations (forefoot to toe) were identified.
Total charges, including a breakdown of component charges, were com-
pared between groups.
Results: Lower extremity bypass procedures decreased 31% from
2000 to 2008 from 5294 to 3636. Hospital based endovascular inter-
ventions increased 113% during the same time points from 2698 to 5748.
Endovascular interventions performed at ambulatory centers showed a
121% increase in just 5 years from 2004 to 2008 (3014 vs 6670*).
Combined hospital and ambulatory based endovascular therapy exceeded
open bypass procedures by over threefold in 2008 (12,419 vs 3636) (Fig
1). Consistent with previous administrative database studies, major am-
putations decreased consistently each year, resulting in a 43% decrease
from 2000 to 2008 (2833 vs 1609), whereas minor amputations were
stable (1354 vs 1362). Total charges were highest for open bypass
($62,946  65,595), followed by hospital based endovascular proce-
dures ($57,995  58,008), and lowest for ambulatory endovascular
procedures ($32,719  16,574) (Table). Comparing specific charges for
hospital based endovascular vs open bypass procedures, higher charges
for medical/surgical supplies and radiology for endovascular procedures
was offset by savings in anesthesia, as well as shorter length of stay as
reflected in smaller charges for ICU/floor, medications, and laboratory
studies. Endovascular procedures at ambulatory centers had substantially
lower charges overall and in all of the major categories. Notably, among
over 20,000 discharges from ambulatory centers, there were two deaths,
and only 10 were transferred to inpatient care.
Conclusion: In Florida, rapid adoption of endovascular procedures,
particularly in ambulatory centers, has led to a decrease in open bypass
procedures and is associated with a continual decrease in major amputations.
For carefully selected patients, endovascular procedures performed in am-
bulatory centers are safe and offer significant cost savings. These data provide
the platform for a prospective, collaborative Florida Vascular Study Group
aimed at prospective quality improvement. * Projected 2008 ambulatory
data based on the first three quarters due to lack of Q4 data at the time of
submission
Table. Total and component charges by type of
procedure and setting
Open
bypass
Endovascular
(hospital)
Endovascular
(ambulatory)
Total charges $61,946 $57,995 $32,719
ICU/floor $ 7547 $ 4806 n/a
Medications/lab
studies
$14,466 $10,574 $ 1622
Medical/surgical
supply
$ 9559 $14,095 $11,151
Radiology
Studies/therapy
$ 3106 $ 8887 $ 7219
OR charges $13,922 $ 9854 $ 8905
Anesthesia charges $ 3487 $ 1007 $ 219
Recovery/observation $ 2025 $ 2183 $ 1176
Other $ 7834 $ 6589 $ 2427
